How CUX1 controls blood stem cell fate
Establishing CUX1 as a determinant of hematopoietic stem cell fate
This project looks at how different amounts of the protein CUX1 change blood stem cells and could help people with blood disorders like myelodysplastic syndrome or anemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11243331 on NIH RePORTER |
What this research studies
Researchers are using a new genetically engineered mouse that reports CUX1 protein levels in individual blood stem and progenitor cells so they can watch how CUX1 varies from cell to cell. They will compare cells with different CUX1 amounts to see how those differences affect stem cell division, self-renewal, and the choice of blood cell types they become. The team links these findings to human conditions where CUX1 is commonly lost, such as clonal hematopoiesis and myelodysplastic syndrome, to better understand why patients develop low blood counts and lineage imbalances. Results could point toward biomarkers or molecular targets for future patient-focused tests or therapies.
Who could benefit from this research
Good fit: People with clonal hematopoiesis, myelodysplastic syndrome, unexplained low blood counts (cytopenias), or related blood disorders would be most directly relevant to the findings of this work.
Not a fit: Patients with conditions unrelated to blood formation or those already stable on effective treatments are unlikely to receive direct benefit from this basic research study.
Why it matters
Potential benefit: If successful, this work could reveal why CUX1 loss leads to abnormal blood formation and point to ways to detect or correct those changes in patients with blood disorders.
How similar studies have performed: Previous research has linked CUX1 loss to clonal hematopoiesis and myelodysplastic syndrome, but using a single-cell CUX1 reporter mouse to track dosage effects on stem cell fate is a novel approach.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mcnerney, Megan — University of Chicago
- Study coordinator: Mcnerney, Megan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.